A preview of this full-text is provided by Canadian Science Publishing.
Content available from Applied Physiology Nutrition and Metabolism
This content is subject to copyright. Terms and conditions apply.
ARTICLE
Improvement of activity-related knee joint discomfort
following supplementation of specific collagen peptides
Denise Zdzieblik, Steffen Oesser, Albert Gollhofer, and Daniel König
Updated online 18 April 2017: The license for this article has been changed to the CC BY 4.0 license. The PDF and HTML versions
of the article have been modified accordingly.
Abstract: The aim of the study was to evaluate the use of specific collagen peptides in reducing pain in athletes with functional
knee problems during sport. Athletic subjects (n= 139) with functional knee pain ingested5gofbioactive collagen peptides (BCP)
or a placebo per day for 12 weeks. The primary outcome of the study was a change in pain intensity during activity, which was
evaluated by the participants and the attending physicians using a visual analogue scale (VAS). As secondary endpoints, pain
intensity under resting conditions, the range of motion of the knee joint, and the use of additional therapeutic options were
assessed. The results revealed a statistically significant improvement in activity-related pain intensity in the verum group
compared with placebo. (⌬VAS
BCP
= 19.5 ± 2.4; ⌬VAS
Placebo
= 13.9 ± 2.1; p= 0.046). The results were confirmed by the physician’s
assessment. (⌬VAS
BCP
= 16.7 ± 1.8; ⌬VAS
Placebo
= 12.2 ± 1.8; p= 0.021). Pain under resting conditions was also improved, but no
significance compared with placebo was detected (⌬VAS
BCP
= 10.2 ± 18.4; ⌬VAS
Placebo
= 7.4 ± 15.2; p= 0.209). Due to the high joint
mobility at baseline, no significant changes of this parameter could be detected. The use of additional treatment options was
significantly reduced after BCP intake. The study demonstrated that the supplementation of specific collagen peptides in young
adults with functional knee problems led to a statistically significant improvement of activity-related joint pain.
Key words: collagen peptides, collagen hydrolysate, athletes, functional joint discomfort, visual analogue scale.
Résumé : Cette étude a pour objectif d’évaluer l’utilisation de peptides de collagène spécifiques pour la diminution de la douleur
chez des athlètes présentant des anomalies fonctionnelles du genou dans le sport. Cent-trente-neuf athlètes présentant une
douleur fonctionnelle au genou consomment tous les jours5gdepeptides bioactifs de collagène (BCP) ou un placebo durant 12
semaines. Le résultat principal de cette étude est la modification, durant l’activité, de l’intensité de la douleur telle qu’évaluée
par les participants et le médecin sur place au moyen d’une échelle visuelle analogue (VAS). On évalue aussi, dans un deuxième
temps, l’intensité de la douleur au repos, l’amplitude de mouvement du genou et l’utilisation de traitements additionnels. Les
résultats révèlent une diminution statistiquement significative de l’intensité de la douleur a
`l’effort dans le groupe expérimental
comparativement au groupe de contrôle (⌬VAS
BCP
= 19,5 ± 2,4; ⌬VAS
Placebo
= 13,9 ± 2,1; p= 0,046). Les résultats confirment
l’évaluation du médecin (⌬VAS
BCP
= 16,7 ± 1,8; ⌬VAS
Placebo
= 12,2 ± 1,8; p= 0,021). La douleur au repos est aussi diminuée, mais pas
de façon significative par rapport au groupe de contrôle (⌬VAS
BCP
= 10,2 ± 18,4; ⌬VAS
Placebo
= 7,4 ± 15,2; p= 0,209). On n’enregistre
pas de modifications significatives de la mobilité du genou probablement a
`cause de la mobilité élevée de l’articulation au début
de l’expérimentation. À la suite de la consommation de BCP, on note une diminution significative des traitements additionnels.
D’après cette étude, la supplémentation en peptides de collagène spécifiques chez de jeunes adultes présentant des anomalies
fonctionnelles du genou suscite une diminution statistiquement significative de la douleur articulaire associée a
`l’exercice
physique. [Traduit par la Rédaction]
Mots-clés : peptides de collagène, hydrolysat de collagène, athlètes, malaises articulaires fonctionnels, échelle visuelle analogue.
Introduction
Collagen peptides are derived from an enzymatic hydrolysis of
collagen, consisting mainly of the amino acids glycine (Gly), pro-
line (Pro), and hydroxyproline (Hyp) (Clemente 2000;Dybka and
Walczak 2009;Oesser and Seifert 2003;Walrand et al. 2008;
Watanabe-Kamiyama et al. 2010). The amino acids sequence and
the molecular weight distribution of the peptides depends on the
raw materials source and the specific production process (Iwai
et al. 2005;Ohara et al. 2007;Saito et al. 2001). Collagen peptides
are classified as a safe food by the European Food Safety Authority
(European Food Safety Authority 2005) and by the Food and Drug
Administration (FDA (U.S. Food and Drug Administration) 2003). It
has been found that collagen peptides are almost completely re-
sorbed in the small intestine (Iwai et al. 2005;Ohara et al. 2007;
Walrand et al. 2008;Watanabe-Kamiyama et al. 2010). About 10%
of the collagen fragments are taken up in peptide form with a size
of 1 to 10 kDa. These peptides are directly transferred from the
gastrointestinal tract into the blood (Iwai et al. 2005;Ohara et al.
2007;Walrand et al. 2008;Watanabe-Kamiyama et al. 2010). Accord-
ing to the results of preclinical trials, a significant amount of these
peptides accumulate in the articular cartilage (Oesser et al. 1999).
Received 14 July 2016. Accepted 10 January 2017.
D. Zdzieblik. Department of Nutrition, University of Freiburg, Department of Sport and Sport Science, Schwarzwaldstraße 175, 79117 Freiburg,
Germany.
S. Oesser. CRI, Collagen Research Institute, Kiel, Germany, Schauenburgerstraße 116, 24118 Kiel.
A. Gollhofer and D. König. University of Freiburg, Department Sport and Sport Science, Schwarzwaldstraße 175, 79117 Freiburg, Germany.
Corresponding author: Denise Zdzieblik (email: denise.zdzieblik@sport.uni-freiburg.de).
Copyright remains with the author(s) or their institution(s). This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
588
Appl. Physiol. Nutr. Metab. 42: 588–595 (2017) dx.doi.org/10.1139/apnm-2016-0390 Published at www.nrcresearchpress.com/apnm on 24 January 2017.